Will Healthcare Growth Help STE Beat on Q1 Earnings?

STERIS plc (STE) is scheduled to release its first-quarter fiscal 2026 results on August 7, with consensus estimates forecasting revenues of $1.36 billion, a 6.2% year-over-year increase, and EPS of $2.32, representing a 14.3% rise. The company anticipates growth across its Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments, driven by factors such as robust procedure volumes, organic revenue growth, and favorable pricing. However, despite these positive growth projections, Zacks' model indicates a lower probability of an earnings beat, given STE's Zacks Rank #3 (Hold) and a negative Earnings ESP of -3.24%.

Analysis

STERIS plc (STE) is approaching its first-quarter fiscal 2026 earnings release with expectations of significant growth, yet faces conflicting signals regarding an earnings beat. Consensus estimates project a 6.2% year-over-year revenue increase to $1.36 billion and a robust 14.3% rise in EPS to $2.32. This anticipated growth is broad-based, with model-projected revenue gains across its core segments: Healthcare (+5.1%), Applied Sterilization Technologies (+6.3%), and Life Sciences (+5.5%). Key drivers include strong procedure volumes in the U.S., stable demand from MedTech customers, and favorable pricing and product mix. However, a critical counterpoint is the Zacks quantitative model, which suggests a lower probability of an earnings surprise. The company holds a Zacks Rank #3 (Hold) and, more significantly, a negative Earnings ESP of -3.24%, a metric that historically correlates with a lower likelihood of beating estimates. This creates a dichotomous outlook where strong underlying business fundamentals are pitted against a statistical model indicating potential for a miss, warranting a cautious stance ahead of the August 7th report.

Key Decisions for Investors

• Investors should weigh the strong fundamental outlook, including projected 14.3% EPS growth, against the quantitative risk of an earnings miss highlighted by the negative Earnings ESP of -3.24%.
• Given the conflicting signals, a prudent approach may be to hold existing positions while awaiting clarity from the actual results and management's updated guidance, particularly concerning capital equipment shipment delays.
• Pay close attention to the performance of the Applied Sterilization Technologies (AST) segment, as its expected 6.3% revenue growth is a key contributor to the overall positive forecast and a bellwether for MedTech customer stability.